National Institute of Biomedical Imaging and Bioengineering; Notice of Public Comment Period, 3541-3542 [05-1278]
Download as PDF
Federal Register / Vol. 70, No. 15 / Tuesday, January 25, 2005 / Notices
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3130,
MSC 7850, Bethesda, MD 20892, (301) 435–
3009, elliotro@csr.nih.gov.
Name of Committee: Endocrinology,
Metabolism, Nutrition and Reproductive
Sciences Intergrated Review Group,
Pregnancy and Neonatology Study Section.
Date: February 17–18, 2005.
Time: 8 a.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: Holiday Inn Select Bethesda, 8120
Wisconsin Ave, Bethesda, MD 20814.
Contact Person: Michael Knecht, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6176,
MSC 7892, Bethesda, MD 20892, (301) 435–
1046, knechtm@csr.nih.gov.
Name of Committee: Integrative,
Functional and Cognitive Neuroscience
Integrated Review Group, Neurotoxicology
and Alcohol Study Section.
Date: February 17–18, 2005.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesdsa, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Joseph G. Rudolph, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5186,
MSC 7844, Bethesda, MD 20892, (301) 435–
2212, josephru@csr.nih.gov.
Name of Committee: Hematology
Integrated Review Group, Hemostasis and
Thrombosis Study Section.
Date: February 17–18, 2005.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Four Points by Sheraton Bethesda,
8400 Wisconsin Avenue, Bethesda, MD
20814.
Contact Person: Jerrold Fried, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2114,
MSC 7840, Bethesda, MD 20892, (301) 435–
2633, friedje@csr.nih.gov.
Name of Committee: Biological Chemistry
and Macromolecular Biophysics Integrated
Review Group Macromolecular Structure and
Function C Study Section.
Date: February 17–18, 2005.
Time: 8:30 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Beacon Hotel and Corporate
Quarters, 1615 Rhode Island Avenue, NW.,
Washington, DC 20036.
Contact Person: Arnold Revzin, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4184,
MSC 7824, Bethesda, MD 20892, (301) 435–
1153, revzina@csr.nih.gov.
Name of Committee: Health of the
Population Integrated Review Group
Epidemiology of Chronic Diseases Study
Section.
Date: February 17–18, 2005.
VerDate jul<14>2003
13:14 Jan 24, 2005
Jkt 205001
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Holiday Inn Select Bethesda, 8120
Wisconsin Ave, Bethesda, MD 20814.
Contact Person: J. Scott Osborne, PhD,
MPH, Scientific Review Administrator,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Room 4114, MSC 7816, Bethesda, MD 20892,
(301) 435–1782, osbornes@csr.nih.gov.
Name of Committee: Cardiovascular
Sciences Integrated Review Group
Cardiovascular Differentiation and
Development Study Section.
Date: February 17–18, 2005.
Time: 8:30 a.m. to 11 a.m.
Agenda: To review and evaluate grant
applications.
Place: Wyndham Washington, DC, 1400 M
Street, NW., Washington DC 20005.
Contact Person: Larry Pinkus, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4132,
MSC 7802, Bethesda, MD 20892, (301) 435–
1214, pinkusl@csr.nih.gov.
Name of Committee: Genes, Genomes, and
Genetics Integrated Review Group Genetic
Variation and Evolution Study Section.
Date: February 17–18, 2005.
Time: 9 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: The River Inn, 924 25th Street, NW.,
Washington DC 20037.
Contact Person: David J. Remondini, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2210,
MSC 7890, Bethesda, MD 20892, 301/435–
1038, remondid@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Mosquitoes.
Date: February 17, 2005.
Time: 3 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone conference Call).
Contact Person: Fouad A. El-Zaatari, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3206,
MSC 7808, Bethesda, MD 20892, (301) 435–
1149, elzaataf@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: January 13, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–1273 Filed 1–24–05; 8:45 am]
BILLING CODE 4140–01–M
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
3541
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Public Comment Period
SUMMARY: The National Institute of
Biomedical Imaging and Bioengineering
(NIBIB) is developing its first 5-year
strategic plan (2005–2009), and invites
the public to provide input regarding
NIBIB’s areas of scientific emphasis,
operational emphasis, and strategic
priorities. The public is invited to
provide comments via the NIBIB Web
site.
Background
The NIBIB was authorized by Public
Law 106–580, which was signed into
law by President William Clinton on
December 29, 2000. The establishment
of NIBIB provided an identity and a
research home for the development and
application of new technologies and
techniques for the delivery of health
care in the 21st century.
The mission of the NIBIB is to
improve human health by leading the
development and accelerating the
application of biomedical technologies.
The Institute is committed to integrating
the engineering and physical sciences
with the life sciences to advance basic
research and medical care.
To accomplish this mission, the
NIBIB has developed a set of goals,
strategies, and objectives designed to
maximize the Institute’s impact on
human health. These goals, strategies,
and objectives provide the framework
and action plan for the Institute’s
direction over the next five years, and
determine how NIBIB will allocate
resources to support and enhance
scientific research.
Request for Comments
The NIBIB wants to develop a process
that considers the views of groups and
individuals who are concerned about
the Institute’s programs. The public is
invited to provide input electronically
into the development of NIBIB’s
strategic plan for 2005–2009. Please
visit the NIBIB Web site at https://
www.nibib1.nih.gov/about/SP/
strategicplan.htm to comment.
Comments Due Date
We are asking that electronic
comments regarding the development of
NIBIB’s strategic plan be received by
February 28, 2005. If you do not have
access to a computer, the NIBIB will
provide you with a copy of the material
that is on the Web site. You may request
E:\FR\FM\25JAN1.SGM
25JAN1
3542
Federal Register / Vol. 70, No. 15 / Tuesday, January 25, 2005 / Notices
this material from Ms. Colleen GuayBroder, Office of Science Policy and
Public Liaison, NIBIB, NIH, 31 Center
Drive MSC 2281, Room 1C14, Bethesda,
MD 20892–2281.
The NIBIB looks forward to working
with the research community and the
public to develop its strategic plan.
Dated: January 14, 2005.
Colleen Guay-Broder,
Director, Office of Science Policy and Public
Liaison, National Institute of Biomedical
Imaging and Bioengineering, National
Institutes of Health.
[FR Doc. 05–1278 Filed 1–24–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Mandatory Guidelines for Federal
Workplace Drug Testing Programs
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Mandatory Guidelines:
Response to Public Comments.
AGENCY:
SUMMARY: In the Federal Register notice
of April 13, 2004 (69 FR 19644), the
Department of Health and Human
Services (‘‘HHS’’ or ‘‘Department’’)
published final changes to the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs.
These changes established specimen
validity testing standards and reporting
procedures for Federal agency urine
specimens collected under the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs.
These changes to the Mandatory
Guidelines were subject to further
comment only on the creatinine
criterion that is part of the requirement
to report a urine specimen as
substituted because the Department
based this criterion on information
received after the comment period on
the proposed changes published on
August 21,2001 closed. After reviewing
the comments received regarding this
issue, the Department has concluded
that the 2 mg/dL creatinine criterion
established in the April 13, 2004,
Federal Register notice (69 FR 19644)
for a substituted specimen is the
appropriate cutoff concentration to use
for reporting a urine specimen as
substituted.
EFFECTIVE DATE: November 1, 2004.
FOR FURTHER INFORMATION CONTACT:
Walter F. Vogl, Ph.D., Division of
Workplace Programs, SAMHSA, Room
#2–1035, 1 Choke Cherry Road,
VerDate jul<14>2003
13:14 Jan 24, 2005
Jkt 205001
Rockville, Maryland 20857, telephone
(240) 276–2600, fax (240) 276–2610, or
e-mail: walter.vogl@samhsa.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
The Mandatory Guidelines for Federal
Workplace Drug Testing
Programs(Mandatory Guidelines)
establish the scientific and technical
guidelines for Federal workplace drug
testing programs and standards for
certification of laboratories engaged in
urine drug testing for Federal agencies,
under authority of section 503 of Pub.
L. 100–71, 5 U.S.C. 7301 note, and E. 0.
No. 12564. The Mandatory Guidelines
were first published in the Federal
Register on April 11, 1988 (53 FR
11979), revised on June 9, 1994 (59 FR
29908), revised on November 13, 1998
(63 FR 63483), and revised on April 13,
2004 (69 FR 19644).
The April 13, 2004, Federal Register
notice finalized the changes to the
Mandatory Guidelines that were
proposed in the Federal Register notice
published on August 21, 2001 (66 FR
43876); established an effective date of
November 1, 2004; but allowed further
public comment on one issue. That is,
comments were requested on the 2 mg/
dL creatinine concentration criterion
that was established as part of the
requirement to report a urine specimen
as substituted. This was left open for
comment because the 2 mg/dL
concentration level was based on
information received after the comment
period closed on the Federal Register
notice published on August 21, 2001.
The additional information that was
provided indicated that it was possible
for an individual to provide a normal
urine specimen with a creatinine
concentration less than the 5 mg/dL
cutoff concentration criterion proposed
in the August 21 notice.
II. Discussion of Public Comments
As stated in the April 13, 2004,
Federal Register notice, the Department
was only accepting comments on the
creatinine criterion. The Department did
receive several comments on other
sections of the Mandatory Guidelines
including the effective date, but these
sections and the effective date were not
open to comment.
Several commenters recommended
that the Department take one or more of
the following actions with regard to the
creatinine criterion:
Comment: Immediately collect
another specimen from the donor when
the creatinine concentration is between
2 mg/dL and 5 mg/dL because this
policy will continue to detect ‘‘truly
substituted’’ specimens.
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Response: The suggestion that a urine
specimen with a creatinine
concentration between 2 mg/dL and 5
mg/dL is ‘‘truly substituted’’ implies
that the cutoff concentration should be
raised to 5 mg/dL to ensure that all
substituted specimens are correctly
identified as substituted specimens. The
Department disagrees with this
suggestion. At the Department of
Transportation Federal Aviation
Administration’s conference held
February 4–6, 2003, to study
substitution and adulteration issues, the
experts attending the conference were
convinced based on evidence presented
that it was possible for some individuals
to produce a valid urine specimen with
a creatinine concentration of less than 5
mg/dL, the level specified in the
Federal Register notice of August 21,
2001. After consideration of data on
creatinine levels, they concluded that
the level should be set at 2 mg/dL.
Lowering the concentration level will
prevent the likelihood of individuals
being falsely accused of substituting
their specimen. The Department also
notes that there is a second criterion for
determining whether a specimen has
been substituted—specific gravity—
which has not been changed.
Comment: Immediately collect
another specimen from the donor when
the creatinine concentration is between
2 mg/dL and 5 mg/dL because
approximately one half of the second
specimens collected from donors in this
creatinine range are tested and reported
drug positive.
Response: The commenter who
submitted this comment did not provide
actual data to justify the claim that
approximately one-half of the second
specimens collected are tested and
reported drug positive. The commenter
based the observation on specimens
between 2 mg/dL and 5 mg/dL that one
Medical Review Officer ordered to have
a second specimen collected. There was
no indication of the number of
specimens that were recollected, the
reason for testing (i.e., random, postaccident, pre-employment), or whether
they were Federal agency, DOT
regulated, or private-sector specimens.
The commenter did say that all of the
recollections that were drug positive
were from males and none from females.
The Department believes this anecdotal
information is not sufficient justification
to require immediately collecting a
second specimen from a Federal
employee or applicant for a Federal
agency testing designated position using
a direct observed collection. The
Department also believes that a urine
specimen that tests negative for drugs, is
dilute, and exhibits no other evidence of
E:\FR\FM\25JAN1.SGM
25JAN1
Agencies
[Federal Register Volume 70, Number 15 (Tuesday, January 25, 2005)]
[Notices]
[Pages 3541-3542]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-1278]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical Imaging and Bioengineering;
Notice of Public Comment Period
SUMMARY: The National Institute of Biomedical Imaging and
Bioengineering (NIBIB) is developing its first 5-year strategic plan
(2005-2009), and invites the public to provide input regarding NIBIB's
areas of scientific emphasis, operational emphasis, and strategic
priorities. The public is invited to provide comments via the NIBIB Web
site.
Background
The NIBIB was authorized by Public Law 106-580, which was signed
into law by President William Clinton on December 29, 2000. The
establishment of NIBIB provided an identity and a research home for the
development and application of new technologies and techniques for the
delivery of health care in the 21st century.
The mission of the NIBIB is to improve human health by leading the
development and accelerating the application of biomedical
technologies. The Institute is committed to integrating the engineering
and physical sciences with the life sciences to advance basic research
and medical care.
To accomplish this mission, the NIBIB has developed a set of goals,
strategies, and objectives designed to maximize the Institute's impact
on human health. These goals, strategies, and objectives provide the
framework and action plan for the Institute's direction over the next
five years, and determine how NIBIB will allocate resources to support
and enhance scientific research.
Request for Comments
The NIBIB wants to develop a process that considers the views of
groups and individuals who are concerned about the Institute's
programs. The public is invited to provide input electronically into
the development of NIBIB's strategic plan for 2005-2009. Please visit
the NIBIB Web site at https://www.nibib1.nih.gov/about/SP/
strategicplan.htm to comment.
Comments Due Date
We are asking that electronic comments regarding the development of
NIBIB's strategic plan be received by February 28, 2005. If you do not
have access to a computer, the NIBIB will provide you with a copy of
the material that is on the Web site. You may request
[[Page 3542]]
this material from Ms. Colleen Guay-Broder, Office of Science Policy
and Public Liaison, NIBIB, NIH, 31 Center Drive MSC 2281, Room 1C14,
Bethesda, MD 20892-2281.
The NIBIB looks forward to working with the research community and
the public to develop its strategic plan.
Dated: January 14, 2005.
Colleen Guay-Broder,
Director, Office of Science Policy and Public Liaison, National
Institute of Biomedical Imaging and Bioengineering, National Institutes
of Health.
[FR Doc. 05-1278 Filed 1-24-05; 8:45 am]
BILLING CODE 4140-01-P